Clinical Trials Logo

Advanced Stage Cancer clinical trials

View clinical trials related to Advanced Stage Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02616588 Completed - Clinical trials for Advanced Stage Cancer

Vets Helping Vets Pilot Study

VHV
Start date: February 2016
Phase: N/A
Study type: Interventional

The overall goal of this study is to evaluate the feasibility of a veteran patient navigator and social work counseling intervention in veterans with advanced stage cancer at the Denver VA Medical Center. This is a tiered intervention: patients first receive the veteran patient navigator component of the intervention, and then if additional patient needs are present they receive the social work counseling component of the intervention. The overall intervention will help veterans communicate their care preferences with their providers.This is a study of behavioral and care strategy interventions and involves no investigational drugs or devices.

NCT ID: NCT01706627 Completed - Clinical trials for Advanced Stage Cancer

Melatonin In Reduction of Chemotherapy-Induced Toxicity (MIRCIT) Trial

MIRCIT
Start date: August 2007
Phase: Phase 2/Phase 3
Study type: Interventional

Meta-analysis of previous studies have shown that melatonin is a beneficial adjutant for reducing chemotherapy-induced toxicity; however no randomized, double-blind, placebo controlled trials have been conducted. This study evaluates the effect of melatonin in improving quality of life and reducing chemotherapy-induced toxicity in advanced cancer patients. This is a multi-center, randomized, double-blind, placebo controlled trial conducted in patients with histologically proven advanced non small cell lung, breast, head and neck or sarcoma cancer. Mixed-block randomization, stratified by center and treatment scheme is used to divide eligible patients into three groups: melatonin 20 mg, 10 mg or matched placebo. The patients are required to take the studied drugs at night (after 21.00 pm) on the first day of chemotherapy and continue daily for six months. Standard treatment is chemotherapy according to each center's standard protocol. Study endpoints are QOL (FACT), adverse event frequency (CTCAE), oxidative stress status, melatonin level, and survival.